

業績目録(令和2年)

教室・部門名 呼吸器内科学

(A-a) 英文著書

なし

(A-b) 和文著書

1. 金子美子. 「ナーシング・グラフィカ EX 疾患と看護 1 呼吸器」禁煙指導 メディカ出版, 東京: pp280-283, 2020.
2. 吉村彰紘, 高山浩一. I 気道・肺疾患 11. 肺癌 E. 原発性肺癌 4 神経内分泌腫瘍. 新呼吸器専門医テキスト改訂第2版. 南江堂, 東京: 531-533, 2020.

(B-a) 英文総説

1. Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. J Clin Med 9: E1362, 2020. (IF=4.242)
2. Okura N, Asanto M, Uchino J, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Fukui M, Takayama K. Endocrinopathies associated with Immune Checkpoint Inhibitor cancer treatment: A Review. J Clin Med 9: E2033, 2020. (IF=4.242)
3. Hamashima R, Uchino J, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Association of immune checkpoint inhibitors with respiratory infections: A review. Cancer Treat Rev. 90: 102109, 2020. (IF=12.111)

(B-b) 和文総説

1. 山田忠明. 分子標的薬に対する抵抗性の分子機構と治療. 分子呼吸器病 24: 42-44, 2020.
2. 山田忠明. EGFR-TKI 耐性. 腫瘍内科 25: 1-8, 2020.
3. 田中理美, 高山浩一. カヘキシアにおけるサルコペニアに対する複合介入. 医学のあゆみ 274(6-7), 577-580, 2020.

(C-a) 英文原著

1. Katayama Y, Shimamoto T, Yamada T, Takeda T, Yamada T, Shiotsu S,

- Chihara Y, Hiranuma O, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Retrospective efficacy analysis of immune checkpoint inhibitor rechallenge in patients with non-small cell lung cancer. *J Clin Med* 9(1): 102, 2020. (IF=4.242)
2. Kanbayashi Y, Ishikawa T, Tabuchi Y, Sakaguchi K, Ouchi Y, Otsuji E, Takayama K, Taguchi T. Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis. *Sci Rep* 10(1):2011, 2020. (IF=4.379)
 3. Imai H, Wasamoto S, Yamaguchi O, Suzuki K, Sugiyama T, Uchino J, Minemura H, Osaki T, Ishii H, Umeda Y, Mori K, Kotake M, Kagamu H, Morozumi N, Taniguchi H, Kasai T, Minato K, Kaira K. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. *J Cancer Res Clin Oncol* 146(2): 457-466, 2020. (IF=4.553)
 4. Takayama K, Ichiki M, Matsumoto T, Ebi N, Akamine S, Tokunaga S, Yamada T, Uchino J, Nakanishi Y. Phase II Study on biweekly combination therapy of gemcitabine plus carboplatin for the treatment of elderly patients with Advanced Non-Small Cell Lung Cancer. *Oncologist* 25(3): 208-e417, 2020. (IF=5.550)
 5. Yamaguchi O, Imai H, Minemura H, Suzuki K, Wasamoto S, Umeda Y, Osaki T, Kasahara N, Uchino J, Sugiyama T, Ishihara S, Ishii H, Naruse I, Mori K, Kotake M, Kanazawa K, Minato K, Kagamu H, Kaira K. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. *Cancer Chemother Pharmacol* 85(4):761-771, 2020. (IF=3.333)
 6. Chihara Y, Iizumi Y, Horinaka M, Goi W, Morita M, Nishimoto E, Sowa Y, Yamada T, Takayama K, Sakai T. The histone deacetylase inhibitor OBP-801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma cells by inducing mitochondrial ASK1-dependent apoptosis. *International Journal of Oncology* 56(3): 848-856, 2020. (IF=5.650)
 7. Sekine I, Shintani Y, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Dosaka-Akita H, Takiguchi Y, Miyaoka E, Okumura M, Yoshino I. A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients. *Cancer Sci*

- 111(5): 1685–1691, 2020. (IF=6.716)
8. Curry JN, Tokuda S, McAnulty P, Yu ASL. Combinatorial expression of claudins in the proximal renal tubule and its functional consequences. *Am J Physiol Renal Physiol* 318(5): F1138–F1146, 2020. (IF=3.377)
 9. Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. *Clin Cancer Res* 26(9): 2244–2256, 2020. (IF=12.531)
 10. Yamada T, Uchino J, Chihara Y, Shimamoto T, Iwasaku M, Tamiya N, Kaneko Y, Kiyomi F, Takayama K. Rationale and design of a phase 2 trial of durvalumab treatment in NSCLC patients ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT Study). *The Adv Med Oncol* 12: 1758835920927841, 2020. (IF=8.168)
 11. Mouri T, Hatamochi C, Uchino J, Takayama K. Education program for male patients with chronic obstructive pulmonary disease to change dietary Behavior *Kobe J. Med. Sci* 66: E82–E89, 2020.
 12. Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, Tsunozuka H, Kosuga T, Konishi H, Moriguchi M, Yasuda H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. *Clin Transl Oncol* 22(6): 919–927, 2020. (IF=3.405)
 13. Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Araya T, Hiraoka N, Ishizuka T, Takeda T, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Akai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K. Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. *J Clin Med* 9(6): 1762, 2020. (IF=4.242)
 14. Kaneko Y, Seko Y, Sotozono C, Ueta M, Sato S, Shimamoto T, Iwasaku M, Yamada T, Uchino J, Hizawa N, Takayama K. Respiratory complications of Stevens–Johnson syndrome (SJS): 3 cases of SJS-induced obstructive

- bronchiolitis *Allergology International* 69: 465-467, 2020. (IF=5.836)
15. Kaneko Y, Mouri T, Seto Y, Nishioka N, Yoshimura A, Yamamoto C, Harita S, Chihara Y, Tamiya N, Yamada T, Uchino J, Takayama K. The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status. *Intern Med* 59(13): 1605-1610, 2020. (IF=1.271)
 16. Takayama K, Takeshita M, Inoue K, Ichiki M, Fujita M, Harada T, Shiraishi Y, Wataya H, Tokunaga S, Yamada T, Uchino J, Sugio K. Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801. *Oncologist* 25(8): e1146-e1157, 2020. (IF=5.550)
 17. Kobayashi K, Soejima K, Fukunaga K, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Takiguchi Y, Miyaoka E, Okumura M, Yoshino I. Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database. *Lung Cancer* 146: 236-243, 2020. (IF=5.705)
 18. Ikeda K, Kusaba T, Tomita A, Watanabe-Uehara N, Ida T, Kitani T, Yamashita N, Uehara M, Matoba S, Yamada T, Tamagaki K. Diverse Receptor Tyrosine Kinase Phosphorylation in Urine-Derived Tubular Epithelial Cells from Autosomal Dominant Polycystic Kidney Disease Patients. *Nephron* 144(10): 525-536, 2020. (IF=2.847)
 19. Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. *Nat Commun* 11(1): 4607, 2020. (IF=14.919)
 20. Ota T, Fukui T, Nakahara Y, Takeda T, Uchino J, Mouri T, Kudo K, Nakajima S, Suzumura T, Fukuoka M. Serum immune modulators during the first cycle of anti-PD-1 antibody therapy in non-small cell lung cancer: Perforin as a biomarker. *Thorac Cancer* 11: 3223-3233, 2020. (IF=3.500)

21. Sakakida T, Ishikawa T, Uchino J, Tabuchi Y, Komori S, Asai J, Arai A, Tsunozuka H, Kosuga T, Konishi H, Hongo F, Inoue M, Hirano S, Ukimura O, Taguchi T, Takayama K, Itoh Y. Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies. *Oncol Lett* 20(4): 14, 2020. (IF=2.967)
22. Imai H, Minemura H, Kishikawa T, Yamada Y, Suzuki K, Umeda Y, Wasamoto S, Kasahara N, Ishihara S, Yamaguchi O, Naruse I, Uchino J, Mori K, Kanazawa K, Shibata Y, Kasai T, Kaburagi T, Kaira K, Minato K. Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥ 75 years) with non-small cell lung cancer: A retrospective analysis *Thorac Cancer* 11(10): 2867-2876, 2020. (IF=3.500)
23. Katayama Y, Yamada T, Chihara Y, Tanaka S, Tanimura K, Okura N, Hirose K, Uda S, Shiotsu S, Hirai S, Hiranuma O, Harada T, Shimamoto T, Iwasaku M, Kaneko Y, Uchino J, Takeda T, Takayama K. Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small cell lung cancer patients. *Sci Rep* 10(1): 17495, 2020. (IF=4.379)

(C-b) 和文原著

なし

(D) 学会発表

I) 特別講演、教育講演等

1. 高山 浩一. 特別講演 進行型小細胞肺癌の薬物療法. 第117回日本肺癌学会中部支部学術集会, 2020, Web開催.
2. 山田 忠明. Year in Review がん分子標的治療薬耐性. 第24回日本がん分子標的治療学会学術集会, 2020, Web開催.
3. 山田 忠明. 篠井・河合賞受賞記念講演 肺がんの治療抵抗性因子の探索と根治を目指した新規治療法の開発. 第61回日本肺癌学会総会, 2020, 岡山

II) シンポジウム、ワークショップ、パネルディスカッション等

1. 山田 忠明. ワークショップ Diver 遺伝子変異肺がんにおける初期治療抵抗性機構の解明. 第61回日本肺癌学会総会, 2020, 岡山.

III) 国際学会における一般発表

1. Kaneko Y, Seto Y, Sotozono C, Ueta M, Sato S, Iwasaku M, Yamada T, Uchino J, Takayama K. Respiratory complications of Stevens-Johnson syndrome (SJS) 3 cases of SJS-induced obstructive bronchiolitis. JSA/WAO Joint Congress 2020. 2020 Sep 17-Oct 20. Web 開催.
2. Kitadai R, Yoshimura A, Yamada T, Okuma Y, Takeda T, Kanematsu T, Uchino J, Nishioka Y, Takayama K. Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. AACR Annual Meeting 2020. 2020 Jun 22-24. Web 開催.
3. Terada N, Kimura H, Miyakawa M, Koba H, Yoneda T, Takeda T, Shirasaki H, Shibata K, Nishi K, Takayama K, Kasahara K. Mutation analysis in cell-free DNA upon development of resistance to afatinib. AACR Annual Meeting 2020. 2020 Jun 22-24. Web 開催.
4. Nishioka N, Naito T, Notsu A, Mori K, Kodama H, Miyawaki E, Miyawaki T, Mamesya N, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takayama K, T, Takahashi T. Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. Virtual Cancer Cachexia Conference 2020. 2020 Sep 10-11. Web 開催.
5. Yamamoto C, Kawashima A, Sawada R, Futamura S. Characteristics of smear-positive pulmonary tuberculosis patients with delayed diagnosis. ERS International Congress 2020. 2020 Sep 7-9. Web 開催.
6. Kaneko Y, Seto Y, Goto T, Fujita Y, Takesako T, Yokomura I, Hiranuma O, Takeda T, T Yamada, Hizawa N, Morimoto Y, Iwasaku M, Yamada T, Uchino J, Takayama K. Preliminary fact-finding survey to support employment and attending school for bronchial asthma patients and caregivers. APSR Assembly Virtual Meeting 2020. 2020 Nov 10-28. Web 開催.
7. Yoshimura A, Yamada T, Atagi S, Taniguchi H, Kaira K, Matsumoto I, Watanabe S, Miura S, Yamaguchi H, Uchino J, Takayama K, Yano S. Impact of pre-treatment AXL expression on EGFR-TKI efficacy in patients with non-small cell lung cancer with EGFR mutation. 2020 KALC International Conference Virtual. 2020 Nov 19-20. Web 開催.
8. Taniguchi Y, Yamada T, Yoshimura A, Taniguchi H, Kaira K, Atagi S, Yano S, Takayama K. Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with

EGFR mutation. ESMO Asia Virtual Congress 2020. 2020 Nov 20-22. Web
開催.

E 研究助成（競争的研究助成金）

総額 662 万円

公的助成

代表 小計 215 万円

1. AMED 革新的がん医療実用化研究事業 令和2年度
悪性腫瘍に伴う悪液質の標準治療の確立フォローアップ研究
高山浩一（代表） 助成金額 40 万円
2. 文部科学省科学研究費 基盤研究（C） 令和元年度～令和3年度
肺がんの「治療抵抗に関わるシグナル指向性」を標的とした画期的治療・
診断法の開発
山田忠明（代表） 助成金額 110 万円
3. 金沢大学がん進展制御研究所 共同研究 令和2年度
EGFR 変異陽性肺癌の各種 EGFR 阻害薬による T790M 耐性変異腫瘍の
heterogeneity の解明
山田忠明（代表） 助成金額 35 万円
4. 文部科学省科学研究費 若手研究 令和2年度～令和4年度
Steven-Johnson 症候群気道粘膜障害における自己免疫機序の解明
金子美子（代表） 助成金額 30 万円

分担 小計 120 万円

1. 厚生労働省科学研究費 平成30年度～令和2年度
アレルギー疾患の患者および養育者の就労・就学支援を推進するための
研究
金子美子（分担） 助成金額 20 万円
2. 厚生労働省科学研究費 令和2年度～令和3年度
重症多形滲出性紅斑に関する調査研究
金子美子（分担） 助成金額 100 万円

II) 財団等からの助成

代表（総額）・小計 327 万円

1. 公益財団法人武田科学振興財団 令和2年度
肺がん治療抵抗性細胞の分子機構の解明と新規治療法の開発

山田忠明（代表） 助成金額 255 万円

2. 公益社団法人大阪ガスグループ福祉財団 令和 2 年度

大阪ガスグループ福祉財団「調査・研究助成」

高齢 COPD 患者の呼吸筋量と吸入力に即したテーラーメイド吸入療法の
検討

金子美子（代表） 助成金額 72 万円